Adedamola Falokun, MD
About Adedamola Falokun, MD
Adedamola Falokun, MD, serves as the Director and Global Safety Officer at Mirati Therapeutics, where he has worked since 2023. He has extensive experience in drug safety and regulatory documentation, having held various positions in healthcare and pharmaceuticals over the past decade.
Current Role at Mirati Therapeutics
Adedamola Falokun serves as the Director and Global Safety Officer at Mirati Therapeutics. He has held this position since 2023, working remotely. In this role, he leads the production of regulatory documentation, including IND Annual Reports, DSUR, and PSUR. He is responsible for collaborating with business partners to create safety data exchange agreements and safety management plans. His expertise in safety characterization during dose escalation and dose selection enhances the company's drug safety practices.
Previous Experience in Drug Safety
Before his current role, Adedamola Falokun worked at Mirati Therapeutics as the Associate Director, Drug Safety Physician from 2022 to 2023. He also served as Medical Director/Center Physician at Takeda Pharmaceuticals America, Inc. from 2019 to 2023. His experience includes working on safety strategies for New Drug Applications (NDAs) and contributing to commercialization efforts. Additionally, he has held positions as a Physician at WellSpan Health and as an Urgent Care Physician at Patient First.
Educational Background
Adedamola Falokun earned his Doctor of Medicine (MD) degree from Morehouse School of Medicine. He completed his Internal Medicine Residency Program at Washington Hospital Center, where he also achieved his Internal Medicine Internship from 2008 to 2009. Additionally, he studied Family Medicine at Virginia Commonwealth University School of Medicine and completed his Family Medicine Residency Program at Riverside Regional Medical Center from 2010 to 2012.
Mentorship and Leadership in Pharmacovigilance
In his current role, Adedamola Falokun mentors Safety Scientists and Medical Reviewers in pharmacovigilance practices. His leadership in this area helps to ensure that safety standards are upheld within the organization. He participates as an industry practice expert in safety characterization, contributing to the overall safety management framework at Mirati Therapeutics.